$1.11+1.04 (+1474.47%)
Azitra Inc (AZTR) is a Biotechnology: Pharmaceutical Preparations company listed on AMEX. In the last 30 days Quantisnow tracked 8 wire items for AZTR, including 5 SEC filings and 3 press releases and news items. The most recent was published Oct 26, 2026.
Price$1.11+1.04 (+1474.47%)
12:00 PM07:45 PM
News · 26 weeks39-33%
2026-05-032026-10-25
Mix1790d
- SEC Filings9(53%)
- Other8(47%)
Latest news
25 items- SECSEC Form 8-K filed by Azitra Inc8-K - Azitra, Inc. (0001701478) (Filer)
- PRAzitra, Inc. Announces Revitalizing Results from Ex Vivo Study of ATR-COSF Demonstrating Ability to Reduce Fine Lines and Improve Elasticity in Human SkinATR-COSF uses a supernatant based formulation containing an active recombinant human domain of the protein, filaggrin.Ex vivo data in two models of recent cosmetic surgery explants showed visible improvements in fine lines, wrinkles and elasticity after a single dose with the ATR-COSF cosmetic product candidateContinued improvement seen up to 48 hoursFirst-in-human study with ATR-COSF initial results anticipated by year endFurther details to be presented in a live presentation at BIO-Europe®BRANFORD, Conn., Oct. 26, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology and high value cosm
- SECSEC Form 8-K filed by Azitra Inc8-K - Azitra, Inc. (0001701478) (Filer)
- PRAzitra, Inc. Announces Reverse Stock SplitCommon Stock Will Begin Trading on a Split-Adjusted Basis on October 26, 2026BRANFORD, Conn., Oct. 16, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 10 pre-split shares. The reverse stock split will become effective at 12:01 A.M. Eastern Time, on October 26, 2026. The Company's common stock will continue to be traded on the NYSE American under the symbol "AZTR" and will begin trading on a split-adjusted basis when the market opens on October 26, 2026. The
- SECAzitra Inc filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Azitra, Inc. (0001701478) (Filer)
- PRAzitra, Inc. Advances ATR-04 Phase 1/2 Clinical Trial to Cohort 2 Following Safety Review Committee ClearanceBRANFORD, Conn., Oct. 1, 2026 /PRNewswire/ -- Azitra, Inc. ("Azitra" or the "Company") (NYSE:AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the completion of Cohort 1 in its Phase 1/2 clinical trial evaluating ATR04-484 as a potential treatment for EGFR inhibitor (EGFRi)-associated skin rash. Following its review of available safety data from patients enrolled in Cohort 1, the study's safety review committee recommended that the trial may proceed to Cohort 2, enabling Azitra to begin enrollment and dosing in the second cohort.The multicenter, randomized, double-blind, vehicle-controlled Phase 1/2 clinica
- SECAzitra Inc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - Azitra, Inc. (0001701478) (Filer)
- SECSEC Form 424B5 filed by Azitra Inc424B5 - Azitra, Inc. (0001701478) (Filer)
- SECAzitra Inc filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Azitra, Inc. (0001701478) (Filer)
- PRAzitra, Inc. to Present at the H.C. Wainwright 28th Annual Global Investment ConferenceBRANFORD, Conn., Sept. 8, 2026 /PRNewswire/ -- Azitra, Inc. ("Azitra" or the "Company") (NYSE:AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology and high value cosmetic proteins and peptides, today announced that Travis Whitfill Ph.D., MPH, Azitra's Co-founder and Chief Operating Officer, will deliver a virtual presentation at the H.C. Wainwright 28th Annual Global Investment Conference, to be held from September 14-16, 2026, in New York City. In the prerecorded presentation, Dr. Whitfill will provide an update on Azitra's recent progress and key pipeline activ
- SECAzitra Inc filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Azitra, Inc. (0001701478) (Filer)
- PRAzitra, Inc. Regains Compliance with NYSE American Continued Listing StandardsBRANFORD, Conn., Aug. 21, 2026 /PRNewswire/ -- Azitra, Inc. ("Azitra" or the "Company") (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology and high value cosmetic proteins and peptides, today announced that it has received written notification from NYSE American LLC ("NYSE American") confirming that the Company has regained compliance with all of the NYSE American continued listing standards set forth in Part 10 of the NYSE American Company Guide. In a letter dated August 19, 2026, NYSE Regulation informed Azitra that the Company has resolved the previous
- SECSEC Form SCHEDULE 13G filed by Azitra IncSCHEDULE 13G - Azitra, Inc. (0001701478) (Subject)
- SECSEC Form SCHEDULE 13G filed by Azitra IncSCHEDULE 13G - Azitra, Inc. (0001701478) (Subject)
- PRAzitra, Inc. Announces Q2 2026 Results and Provides Business UpdatesBRANFORD, Conn., Aug. 12, 2026 /PRNewswire/ -- Azitra, Inc. ("Azitra" or the "Company") (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology and high value cosmetic proteins and peptides, today reported financial results for the quarter ended June 30, 2026, and provided a business update. Q2 2026 and Recent Business HighlightsReported the first preclinical data from ATR-COSF demonstrating breakthrough repeat-dose distribution, controlled delivery into targeted skin layers and anti-wrinkle activity in ex vivo human skin, supporting advancement toward a plann
- SECAzitra Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Azitra, Inc. (0001701478) (Filer)
- SECSEC Form 10-Q filed by Azitra Inc10-Q - Azitra, Inc. (0001701478) (Filer)
- SECAzitra Inc filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Azitra, Inc. (0001701478) (Filer)
- PR/C O R R E C T I O N -- Azitra, Inc./In the news release, Azitra, Inc. Announces Breakthrough Repeat Dose and Anti-Wrinkle Ex Vivo Results for ATR-COSF Program, Demonstrating Increased Distribution and Elasticity, issued 15-Jul-2026 by Azitra, Inc. over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows, with additional details at the end: Azitra, Inc. Announces Breakthrough Repeat Dose and Anti-Wrinkle Ex Vivo Results for ATR-COSF Program, Demonstrating Increased Distribution and Elasticity ATR-COSF uses a supernatant based formulation containing an active recombinant human domain of the protein, filaggrin ("rHDfilaggrin"). This S. epidermis derived supernatant is in
- PRAzitra, Inc. Announces Breakthough Repeat Dose and Anti-Wrinkle Ex Vivo Results for ATR-COSF Program, Demonstrating Increased Distribution and ElasticityATR-COSF uses a supernatant based formulation containing an active recombinant human domain of the protein, filaggrin ("rHDfilaggrin"). This S. epidermis derived supernatant is in development as a high value cosmetic ingredientEx vivo data successfully showed controlled distribution of the rHDfilaggrin into the stratum granulosum in increased amounts over prior single dose experiments in human skin Single dose ex vivo experiments established improvements in elasticity and reduced the appearance of new fine lines and wrinkles in human skin BRANFORD, Conn., July 15, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therap
- SECSEC Form SCHEDULE 13G filed by Azitra IncSCHEDULE 13G - Azitra, Inc. (0001701478) (Subject)
- INSIDERPresident and CEO Salva Francisco D. converted options into 4,064,050 shares, increasing direct ownership by 18,273% to 4,086,291 units (SEC Form 4)4 - Azitra, Inc. (0001701478) (Issuer)
- SECAzitra Inc filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Azitra, Inc. (0001701478) (Filer)
- PRAzitra, Inc. CEO Issues Letter to Shareholders Detailing Strategic Reorientation Initiatives and Outlook for 2026 and BeyondBRANFORD, Conn., June 17, 2026 /PRNewswire/ -- Azitra, Inc. ("Azitra" or the "Company") (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that Francisco Salva, Chief Executive Officer of Azitra, has issued a Letter to Shareholders detailing the Company's strategic growth initiatives, recent accomplishments and outlook for 2026 and beyond. The full text of the letter follows. A MESSAGE FROM OUR CHIEF EXECUTIVE OFFICERTo my fellow shareholders,The first half of 2026 signaled an important inflection point in Azitra's history. During this pe
- PRAzitra, Inc. to Present at 2026 BIO International ConventionBRANFORD, Conn., June 16, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that Cofounder and Chief Operating Officer, Travis Whitfill Ph.D., MPH, will present at BIO International Convention, being held June 22-25, 2026, in San Diego, California. The presentation will highlight recent updates and progress in Azitra's pipeline, including the launch of an innovative protein and peptide program for the cosmetic and cosmeceutical markets leveraging proprietary filaggrin technologies.Presentation Details:Ev
AZTR FAQ
6 questionsWhat is the latest news on AZTR?
In the last 30 days Quantisnow tracked 8 wire items for AZTR: 5 SEC filings and 3 press releases and news items. The most recent was published on October 26, 2026.Where does AZTR stock trade?
Azitra Inc (AZTR) is listed on AMEX.What sector and industry is AZTR in?
Azitra Inc operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Azitra Inc go public?
Azitra Inc (AZTR) completed its IPO in 2023.What companies are similar to AZTR?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare AZTR side-by-side with any of them on Quantisnow.How can I track AZTR on Quantisnow?
Quantisnow aggregates Azitra Inc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AZTR to receive live email and push alerts on every new disclosure.